Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.69 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.69 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.59 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.59 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.69 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.59 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155070 | 0.99 | ALDH1A1 (0.70) | ALDH1A1HSD17B10MAPTKMT2ACYP3A4 | |
| SCHEMBL1649485 | 0.99 | ALDH1A1 (0.70) | ALDH1A1HSD17B10MAPTKMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL1649518 | 0.98 | ALDH1A1 (0.68) | ALDH1A1HSD17B10MAPTKMT2ACYP3A4 | |
| SCHEMBL11625260 | 0.90 | HSD17B10 (0.57) | ALDH1A1HSD17B10MAPTKMT2ACYP3A4 | |
| SCHEMBL11084708 | 0.87 | ALDH1A1 (0.53) | ALDH1A1HSD17B10MAPTKMT2ACYP3A4 | |
| SCHEMBL11084713 | 0.87 | ALDH1A1 (0.53) | ALDH1A1HSD17B10MAPTKMT2ACYP3A4 | |
| SCHEMBL11078184 | 0.86 | PLCG1 (0.55) | ALDH1A1HSD17B10MAPTKMT2ACYP3A4 | |
| SCHEMBL11078185 | 0.86 | PLCG1 (0.55) | ALDH1A1HSD17B10MAPTKMT2ACYP3A4 | |
| SCHEMBL11542683 | 0.86 | ALDH1A1 (0.72) | ALDH1A1HSD17B10MAPTKMT2ACYP3A4 | |
| SCHEMBL11739783 | 0.86 | ALDH1A1 (0.72) | ALDH1A1HSD17B10MAPTKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4609871-A1 | PROBIOTIC COMPOSITION FOR TREATING IBS | Pronaos s.r.o. (CZ) | 2025-09-03 | — | — | EP | claimed |
| EP-4609872-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING IBS | Pronaos s.r.o. (CZ) | 2025-09-03 | — | — | EP | claimed |
| US-20250082694-A1 | PROBIOTICS FOR USE IN BOOSTING THE IMMUNE SYSTEM | INT N&H DENMARK APS (DK) | 2025-03-13 | — | — | US | claimed |
| CN-116121130-B | Composite probiotics fermentation composition for improving sleep quality and application thereof | 中科宜康（北京）生物科技有限公司 | 2024-10-08 | — | — | CN | claimed |
| CN-118402617-A | Application of composite probiotics in improving intestinal flora fatigue resistance of antagonistic athletes | 山东体育学院 | 2024-07-30 | — | — | CN | claimed |
| EP-4373504-A1 | PROBIOTICS FOR USE IN BOOSTING THE IMMUNE SYSTEM | International N&H Denmark ApS (DK) | 2024-05-29 | — | — | EP | claimed |
| CN-116144711-A | Licorice probiotics fermentation preparation and preparation method thereof | 北京中医药大学 | 2023-05-23 | — | — | CN | claimed |
| EP-4178597-A2 | PROBIOTICS FOR USE IN THE PREVENTION OR TREATMENT OF ILLNESS AND/OR SYMPTOMS ASSOCIATED WITH CORONAVIRUSES | DuPont Nutrition Biosciences ApS (DK) | 2023-05-17 | — | — | EP | claimed |
| CN-116121130-A | Composite probiotics fermentation composition for improving sleep quality and application thereof | 中科宜康（北京）生物科技有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-116005464-A | Manufacturing method and product of cationic polyester blended air-textured uvioresistant heat-insulating fabric | 浙江多元纺织科技(集团)有限公司 | 2023-04-25 | — | — | CN | claimed |
| CN-116018152-A | Probiotics for preventing or treating coronavirus-related diseases and/or symptoms | 杜邦营养生物科学有限公司 | 2023-04-25 | — | — | CN | claimed |
| WO-2023001658-A1 | PROBIOTICS FOR USE IN BOOSTING THE IMMUNE SYSTEM | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2023-01-26 | — | — | WO | claimed |
| CN-115191636-A | Reconstituted tobacco with high sugar-alkali ratio and preparation method thereof | 云南瑞升烟草技术（集团）有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-110309970-B | Docker-based power system data prediction method and device | 南瑞集团有限公司 | 2022-07-19 | — | — | CN | claimed |
| US-20260140407-A1 | ELECTROCHROMIC SHEET AND ELECTROCHROMIC DEVICE | SUMITOMO BAKELITE CO., LTD. (JP) | 2026-05-21 | — | — | US | disclosed |
| EP-4726466-A1 | ELECTROCHROMIC LENS, ELECTROCHROMIC SHEET, AND ELECTROCHROMIC DEVICE | Sumitomo Bakelite Co.Ltd. (JP) | 2026-04-15 | — | — | EP | disclosed |
| WO-2026042946-A1 | COMPOSITION FOR STABILIZING NUCLEIC ACIDS, AND METHOD USING SAME | 포항공과대학교 산학협력단 | 2026-02-26 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| EP-1438942-A1 | An otorhinological drug delivery device | Schering Oy (FI) | 2004-07-21 | — | — | EP | disclosed |
| US-4386070-A | CEPHALEXIN OR PIVCEPHALEXIN WITH NALIDIXIC ACID | AUSONIA FARMACEUTICI S.R.L. (IT) | 1983-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260140407-A1 | ELECTROCHROMIC SHEET AND ELECTROCHROMIC DEVICE | GJB2, LNPK, KCNN2 | ADRA1A 4581/4885HTR2B 3599/4885ESR1 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.